- Product Details
Keywords
- Birinapant
- 1260251-31-7
- 98% purity
Quick Details
- ProName: Birinapant
- CasNo: 1260251-31-7
- Molecular Formula: C42H56F2N8O6
- Appearance: powder
- Application: intermediate
- DeliveryTime: in stock
- PackAge: accroding to the need
- Port: Shanghai Port
- ProductionCapacity: 100 Kilogram/Day
- Purity: 98% purity
- Storage: Sealed in dry,Room Temperature
- Transportation: air,sea and courier
- LimitNum: 1 Gram
- Grade: Industrial Grade,Pharma Grade,Electron...
Superiority
Product Name: Birinapant
Synonyms: Birinapant;Birinapant (TL32711);TL 32711;Birinapant(TL32711)/TL-32711/TL32711/TL-32711;(2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide;Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-, (2S,2'S)-;(2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide Birinapant TL 32711;Birinapant (2S,2'S)-N,N'-[(6,6'-Difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-propanamide
CAS: 1260251-31-7
MF: C42H56F2N8O6
MW: 806.94
Mol File: 1260251-31-7.mol
Details
Birinapant Chemical Properties
Boiling point 1090.5±65.0 °C(Predicted)
density 1.320±0.06(20.0000℃)
pka 13.99±0.46(Predicted)
CAS DataBase Reference 1260251-31-7
Safety Information
HS Code 29339900
MSDS Information
Birinapant Usage And Synthesis
Enzyme inhibitor This rotationally symmetric SMAC mimetic antagonist and anticancer agent (FW = 806.94 g/mol; CAS 1260251-31-7) targets cellular Inhibitor of Apoptosis Protein (or cIAP1; Kd of <1 nM), arguably the most potent mammalian caspase inhibitor, showing single-agent efficacy due to its panIAP antagonism and causing rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. When administered in combination with TNF-α, Birinapant is effective against a melanoma cell line with acquired resistance to BRAF inhibitors